|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 239/96 | |
| C07D 401/06 | |||
| A61K 31/517 | |||
| A61P 9/00 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2709990 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12765230.3 |
| Europos patento paraiškos padavimo data | 2012-03-31 | |
| (97) | Europos patento paraiškos paskelbimo data | 2014-03-26 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-06-12 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/CN2012/073362 |
| Data | 2012-03-31 |
| (87) | Numeris | WO 2012/130166 |
| Data | 2012-10-04 |
| (30) | Numeris | Data | Šalis |
| 201110082475 | 2011-04-01 | CN | |
| PCT/CN2011/0770 | 2011-07-11 | WO |
| (72) |
CAI, Sui Xiong, CN
TIAN, Ye Edward, CN
DONG, Haijun, CN
XU, Qingbing, CN
WU, Lizhen, CN
LIU, Lijun, CN
JIANG, Yangzhen, CN
BAO, Qingli, CN
WANG, Guoxiang, CN
YIN, Feng, CN
GU, Chengyun, CN
HU, Xiuhua, CN
WANG, Xiaozhu, CN
KANG, Sishun, CN
CHEN, Shengzhi, CN
|
| (73) |
Impact Therapeutics, Inc.,
Floor 9 10 Xinghuo Road Nanjing, Jiangsu 210061,
CN
|
| (54) | 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer |
| 1-((3-((1-Piperazinyl)carbonyl)phenyl)methyl)-2,4(1H,3H)-quinazolinedione derivatives as PARP inhibitors for treating cancer |